靶向CXCR4的肿瘤诊疗一体化
本文综述了C-X-C趋化因子受体4(CXCR4)在多种肿瘤中上调,可作为诊疗一体化的分子影像与内放射治疗靶点。[68Ga]PentixaFor PET已用于实体瘤(如肾上腺皮质癌、小细胞肺癌)和血液系统恶性肿瘤(如多发性骨髓瘤、边缘区淋巴瘤、套细胞淋巴瘤)的评估,并据此筛选适合[177Lu]/[90Y]PentixaTher治疗的患者;该诊疗一体化概念已用于造血干细胞移植前的预处理方案。
要点
- CXCR4在多种肿瘤中上调,是诊疗一体化的合适靶点。
- [68Ga]PentixaFor PET可用于实体瘤和血液系统恶性肿瘤的评估。
- PET定量CXCR4可筛选适合[177Lu]/[90Y]PentixaTher治疗的患者。
核心结论
- CXCR4靶向诊疗一体化可用于晚期血液系统恶性肿瘤的分子影像与内放射治疗。
研究设计与样本
- 本文为综述,概述CXCR4靶向分子影像的当前应用并介绍其诊疗一体化概念。
主要发现
- [68Ga]PentixaFor PET已证明可用于实体瘤(包括肾上腺皮质癌或小细胞肺癌)的全面评估。
- [68Ga]PentixaFor对血液系统恶性肿瘤(如多发性骨髓瘤、边缘区淋巴瘤或套细胞淋巴瘤)也提供了极好的读出。
- 基于PET的CXCR4体内定量可筛选适合[177Lu]/[90Y]PentixaTher治疗的候选者。
- 该CXCR4靶向诊疗一体化概念已用作造血干细胞移植前的预处理方案,并对高度辐射敏感的恶性组织(如血液系统)达到足够的抗淋巴瘤/抗肿瘤活性。
- 为增加安全边际,常规进行治疗前剂量测定以确定最佳活性,从而提高疗效并减少脱靶不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A growing body of literature reports on the upregulation of C-X-C motif chemokine receptor 4 (CXCR4) in a variety of cancer entities, rendering this receptor as suitable target for molecular imaging and endoradiotherapy in a theranostic setting. For instance, the CXCR4-targeting positron emission tomography (PET) agent [68 Ga]PentixaFor has been proven useful for a comprehensive assessment of the current status quo of solid tumors, including adrenocortical carcinoma or small-cell lung cancer. In addition, [68 Ga]PentixaFor has also provided an excellent readout for hematological malignancies, such as multiple myeloma, marginal zone lymphoma, or mantle cell lymphoma. PET-based quantification of the CXCR4 capacities in vivo allows for selecting candidates that would be suitable for treatment using the theranostic equivalent [177Lu]/[90Y]PentixaTher. This CXCR4-directed theranostic concept has been used as a conditioning regimen prior to hematopoietic stem cell transplantation and to achieve sufficient anti-lymphoma/-tumor activity in particular for malignant tissues that are highly sensitive to radiation, such as the hematological system. Increasing the safety margin, pretherapeutic dosimetry is routinely performed to determine the optimal activity to enhance therapeutic efficacy and to reduce off-target adverse events. The present review will provide an overview of current applications for CXCR4-directed molecular imaging and will introduce the CXCR4-targeted theranostic concept for advanced hematological malignancies.
引用
- Buck AK, Serfling SE, Lindner T, et al. CXCR4-targeted theranostics in oncology. Eur J Nucl Med Mol Imaging. 2022. PMID: 35674738. doi:10.1007/s00259-022-05849-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。